Sign up
Pharma Capital

ANGLE continues to make progress with Parsortix

It was a busy few days at the Third International Advances in Circulating Tumour Cells (ACTC) Symposium in Greece last week
cancer cell
Parsortix has enabled researchers to observe the ‘micro-tentacle’ structures on the surface of the CTCs

As this morning’s three updates confirm, liquid biopsy company ANGLE PLC (LON:AGL) continues to make progress with its Parsortix technology.

Parsortix allows researchers to isolate and capture cancer cells which are then harvested for analysis. By giving researchers more information about an individual’s specific disease make-up, patients should be able to receive a more tailored treatment.

First CTCs successfully cultured using Parsortix

ANGLE announced today that one of its customers has successfully grown circulating tumour cells (CTCs) harvested by the Parsortix system.

The cells have continued to multiply several months after the initial harvest which has given researchers more cells to analyse and investigate.

"This is the first time that a patient's CTCs harvested by ParsortixTM have been successfully cultured,” said ANGLE chief executive and founder Andrew Newland.

“The ParsortixTM system's capability to harvest living, viable cancer cells is a key differentiator and we believe this will lead to new avenues of research using ParsortixTM."

WATCH: ANGLE to offer a full liquid biopsy 'sample to answer' solution following Axela acquisition

Those results were presented at the Third International Advances in Circulating Tumour Cells (ACTC) Symposium in Greece last week.

At the same conference, data from a recent study assessing drug response on live CTCs harvested from a simple blood test using Parsortix was also presented.

Potential new use for Parsortix

Professor Stuart Martin from the University of Maryland' School of Medicine used the Parsortix system to isolate CTCs from the blood of breast cancer patients.

Those recovered cells were then held in place within the Parsortix cassette using cell tethering technology allowing researchers to observe the cells and in particular the ‘micro-tentacle’ structures on the surface of the CTCs.

The structures have been shown to be important to metastasis – cancer that spreads to other parts of the body – by allowing the CTCs to take root in a distant organ.

The entire harvesting and imaging technique could be completed within six hours of patient blood draw, ANGLE said.

Prof Martin’s team were then able to examine the effect of different drugs on the CTCs.

 "This is an unexpected new use of the ParsortixTM system, which could allow major progress in identifying effective drugs for an individual patient's cancer that may arrest or limit metastasis, a process that is ultimately responsible for over 90% of cancer deaths,” added Newland.

“Our vision is that a liquid biopsy using ParsortixTM to harvest circulating tumour cells from a simple blood test will one day be routinely used to support personalised medicine for all cancer patients.”

View full AGL profile

ANGLE plc Timeline

Newswire

ANGLE raises another £2.8mln

View All

Related Articles

scientist in a lab
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.